MDT

89.97

+2.2%↑

MDT

89.97

+2.2%↑

MDT

89.97

+2.2%↑

MDT

89.97

+2.2%↑

MDT

89.97

+2.2%↑

Search

Exelixis Inc

Closed

Sector Healthcare

36.84 4.87

Overview

Share price change

24h

Current

Min

36.53

Max

36.96

Key metrics

By Trading Economics

Income

140M

Sales

27M

567M

P/E

Sector Avg

19.926

73.394

EPS

0.55

Profit margin

24.678

Employees

1,147

EBITDA

171M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+1.68 upside

Dividends

By Dow Jones

Next Earnings

29 Apr 2025

Market Stats

By TradingEconomics

Market Cap

349M

9.8B

Previous open

31.97

Previous close

36.84

News Sentiment

By Acuity

50%

50%

157 / 393 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Exelixis Inc Chart

Past performance is not a reliable indicator of future results.

Related News

22 Feb 2025, 00:16 UTC

Hot Stocks

Stocks to Watch: Alamos Gold, Booking Holdings

22 Feb 2025, 16:33 UTC

Earnings
Acquisitions, Mergers, Takeovers

Berkshire Operating Earnings Rose 71% to $14.5 Billion in Fourth Quarter -- Barrons.com

22 Feb 2025, 15:15 UTC

Earnings
Acquisitions, Mergers, Takeovers

Berkshire Operating Earnings Rose 71% to $14.5 Billion in Fourth Quarter -- Barrons.com

22 Feb 2025, 14:32 UTC

Earnings
Acquisitions, Mergers, Takeovers

Berkshire Operating Earnings Rose 71% to $14.5 Billion in Fourth Quarter -- Barrons.com

22 Feb 2025, 13:49 UTC

Earnings
Acquisitions, Mergers, Takeovers

Berkshire Operating Earnings Rose 71% to $14.5 Billion in Fourth Quarter -- Barrons.com

22 Feb 2025, 13:22 UTC

Earnings
Acquisitions, Mergers, Takeovers

Berkshire Operating Earnings Rose 71% to $14.5 Billion in Fourth Quarter -- Barrons.com

21 Feb 2025, 23:22 UTC

Top News

DOGE Aide's IRS Access Won't Include Personal Information -- Update

21 Feb 2025, 23:20 UTC

Earnings

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

21 Feb 2025, 22:34 UTC

Market Talk

L'Oréal Cuts Exposure to Chinese Market, Grows Emerging Markets -- Market Talk

21 Feb 2025, 22:12 UTC

Top News

DOJ Investigates Medicare Billing Practices at UnitedHealth -- 2nd Update

21 Feb 2025, 21:54 UTC

Top News

Why Is Warren Buffett Hoarding So Much Cash? -- 2nd Update

21 Feb 2025, 21:51 UTC

Earnings

Tesla Stock Falls. Recalls and Rivian Are in the News. -- Barrons.com

21 Feb 2025, 21:50 UTC

Market Talk
Earnings

Financial Services Roundup: Market Talk

21 Feb 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 Feb 2025, 21:50 UTC

Top News

DOGE Aide's IRS Access Won't Include Personal Information -- WSJ

21 Feb 2025, 21:48 UTC

Market Talk
Earnings

L'Oréal Tops Estée Lauder in Luxury U.S. Market, CEO Says -- Market Talk

21 Feb 2025, 21:35 UTC

Market Talk

Bulk of U.S. Imports From Canada Used to Make U.S. Goods -- Market Talk

21 Feb 2025, 21:28 UTC

Top News

Why Is Warren Buffett Hoarding So Much Cash? -- Update

21 Feb 2025, 21:24 UTC

Top News

Major U.S. Stock Indexes Give Up Gains From the Week -- WSJ

21 Feb 2025, 21:19 UTC

Market Talk

Mexico's Inflation Seen Up in Early February -- Market Talk

21 Feb 2025, 20:15 UTC

Market Talk

Global Equities Roundup: Market Talk

21 Feb 2025, 20:15 UTC

Market Talk

JPMorgan Chase Branch Expansion Portends Deposit Growth -- Market Talk

21 Feb 2025, 20:05 UTC

Market Talk

Oil Futures Retreat Into the Weekend Again -- Market Talk

21 Feb 2025, 19:58 UTC

Market Talk

U.S. Natural Gas Futures Post Third Straight Weekly Gain -- Market Talk

21 Feb 2025, 19:29 UTC

Market Talk

Gold Slides After Finding Record High -- Market Talk

21 Feb 2025, 19:26 UTC

Top News

Major U.S. Stock Indexes Slip; UnitedHealth Pulls Down DJIA -- WSJ

21 Feb 2025, 19:05 UTC

Market Talk

Business Conditions Seen as Favoring Corporate Credit -- Market Talk

21 Feb 2025, 19:02 UTC

Market Talk

Global Energy Roundup: Market Talk

21 Feb 2025, 19:02 UTC

Market Talk

Corporate Credit Expected to Be Hit Unevenly by Trade Wars -- Market Talk

21 Feb 2025, 19:00 UTC

Market Talk

Long-Term Treasury Yields Expected to Rise -- Market Talk

Peer Comparison

Price change

Exelixis Inc Forecast

Price Target

By TipRanks

1.68% upside

12 Months Forecast

Average 37.47 USD  1.68%

High 45 USD

Low 29 USD

Based on 20 Wall Street analysts offering 12 month price targets forExelixis Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

20 ratings

12

Buy

8

Hold

0

Sell

Technical Score

By Trading Central

35.3696 / N/ASupport & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Neutral Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

157 / 393 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Exelixis Inc

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.